Demand and volumenegative · 4 filings
“This decrease was mainly due to price reductions and lower demand due to market dynamics.”10-Q · Apr 29, 2026 ↗
Teva Pharmaceutical Industries Limited
TEVA
Market read
Teva Pharmaceutical Industries Limited's current read is isolated; its market group is not confirming.
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.
What changed
- Revenue increased 2.3% versus the comparable filing period.
- Operating cash flow covered only -0.11x net income.
Company-1.4% todayVolume comparison unavailable
Market group0 of 1 activeGeneric Pharmaceuticals · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- TEVA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if TEVA's group or a disclosed connection begins moving with it.
Research brief
The story so far
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 28 directly disclosed connections are confirming.
Evidence that supports
- Revenue increased 2.3% versus the comparable filing period.
- Operating margin improved 3.0 percentage points.
- Net income increased 72.4% versus the comparable filing period.
Evidence that challenges
- Operating cash flow covered only -0.11x net income.
What would clarify the read
- TEVA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements180
Verified relationships12
Evidence supporting the case
- Operating margin changed +14.3 percentage points in the latest annual period.
- Net margin changed +18.1 percentage points in the latest annual period.
- Operating cash flow covered net income at 1.17x in the latest annual period.
Evidence challenging the case
- Diluted shares increased 2.8% in the latest annual period.
- Demand and volume has repeated adverse evidence across 4 filings.
- Pricing and mix has repeated adverse evidence across 4 filings.
Questions before a position
- P/E is 55% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
36.346m+19.3%12m+84.7%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$15.9B-4.7%$0.38+1.1%
2022-12-31$14.9B-6.0%$-2.20+0.3%
2023-12-31$15.8B+6.2%$-0.50+0.8%
2024-12-31$16.5B+4.4%$-1.45+1.1%
2025-12-31$17.3B+4.3%$1.21+2.8%
What management says matters
Persistent and emerging business drivers
Pricing and mixnegative · 4 filings
“This decrease was mainly due to price reductions and lower demand due to market dynamics.”10-Q · Apr 29, 2026 ↗
Legal and regulatory exposurenegative · 3 filings
“The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the third quarter of 2026.”10-Q · Apr 29, 2026 ↗
Restructuring and cost reductionsmixed · 3 filings
“82 Table of Contents The critical accounting estimates relate to the following: • Revenue Recognition and SR&A in the United States • Income Taxes • Contingencies • Impairment of Property, Plant and Equipment Revenue Recognition and SR&A in the United States…”10-K · Feb 3, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.4× · EV/sales 2.2×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
36.34-1.4% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for TEVA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
The latest filing presents a mixed picture
10-Q filed 2026-04-29 against the comparable filing from 2025-05-07.
OperationsconstructiveEvidence score +3
liquiditycautiousEvidence score -1
valuationmixed
What improved
- Revenue increased 2.3% versus the comparable filing period.
- Operating margin improved 3.0 percentage points.
- Net income increased 72.4% versus the comparable filing period.
What weakened
- Operating cash flow covered only -0.11x net income.
Filing receipts
“The lower cash flow used in operating activities in the first quarter of 2026 was mainly due to favorable timing and mix of sales and collections in our U.S. segment as well as lower payments of interest, partially offset by higher performance incentive payments to employees.”
“In local currency terms, revenues decreased by 14%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.”
“In local currency terms, revenues decreased by 2%, mainly due to net price reductions and lower volumes.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
The relationships behind TEVA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ALVOFiling-linked namepartnerApr 29, 2026 ▾
“Biosimilar Products Pipeline We have additional biosimilar products in development internally and with our partners that are in various stages of development, including confirmatory clinical trials for biosimilars to Entyvio ® (vedolizumab) and Entyvio ® SC (…”
RPRXRoyalty Pharma plcpartnerFeb 3, 2026 ▾
“In line with our Pivot to Growth strategy, and our focus on internal growth that leverages our R&D capabilities, we have entered into, and expect to pursue, in-licensing, acquisition, collaboration, funding and other strategic opportunities to supplement and…”
Depended on by
HALOHalozyme Therapeutics, Inc.supplierMay 11, 2026 ▾
“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 28 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TEVA is currently a Leader in the organic co-movement group Generic Pharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for TEVA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.